Company: MDCXW
Filing Date: 2025-05-27
Form Type: S-1
Source: 0001062993-25-010333
Chunk: 205

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-27
Form: S-1
Chunk 205
---
 offering shown in the table below is based on an aggregate of 13,572,737 common shares outstanding on May 21, 2025. Because the purchase price to be paid by the Selling Shareholders for common shares, if any, that we may elect to sell to the Selling Shareholder in one or more Advances from time to time under the SEPA will be determined on the applicable dates for such Advances, the actual number of common shares that we may sell to the Selling Shareholder under the SEPA may be fewer than the number of shares being offered for resale under this prospectus. The fourth column in the table below assumes the resale by the Selling Shareholder of all of the common shares being offered for resale pursuant to this prospectus.

We have determined beneficial ownership in accordance with the rules of the SEC.

|                   |     | Number of Common Shares 
      Beneficially Owned |     |         |     |   Maximum Number of 
 Common Shares Being 
             Offered |           | Common Shares Beneficially Owned After the 
 Offered Common Shares Are Sold             |         |   |
| Name of Selling   
 Securityholder    |     |               Number(1) |     | Percent |     |                     | Number(2) |                                            | Percent |   |
| YA II PN, Ltd.(3) |     |                 105,840 |     | *       |     |           3,710,000 |           | -                                          |         | * |

__________________

*Less than one percent.

(1)Represents 105,840 Commitment Shares we issued to the Selling Shareholder in consideration for entering into the SEPA with us. In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that the Selling Shareholder may be required to purchase under the SEPA, because the issuance of such shares is at our discretion and is subject to conditions contained in the SEPA, the satisfaction of which are entirely outside of the Selling Shareholder's control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the Advances of common shares under the SEPA are subject to certain agreed upon maximum amount limitations set forth in the SEPA. Also, the SEPA prohibits us from issuing and selling any common shares to the Selling Shareholders to the extent such shares, when aggregated with all other common shares then beneficially owned by the Selling Shareholder, would cause the Selling